SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Forecast, Price Target & Analyst Ratings

FRA:1SXP • DE000A3ENQ51

Current stock price

14.94 EUR
+0.3 (+2.05%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SCHOTT PHARMA AG& CO KGAA (1SXP.DE).

Forecast Snapshot

Consensus Price Target

Price Target
€19.93
+ 33.40% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 13, 2026
Period
Q2 / 2026
EPS Estimate
€0.22
Revenue Estimate
250.64M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
76.84%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
€19.93
Upside
+ 33.40%
From current price of €14.94 to mean target of €19.93, Based on 19 analyst forecasts
Low
€13.13
Median
€19.99
High
€27.20

Price Target Revisions

1 Month
0.00%
3 Months
-6.13%

Price Target Summary

19 Wall Street analysts provided a forecast for the next 12 months for 1SXP.DE. The average price target is 19.93 EUR. This implies a price increase of 33.4% is expected in the next year compared to the current price of 14.94.
The average price target has been revised downward by 6.13% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

1SXP Current Analyst Rating1SXP Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8

Analyst Ratings History

1SXP Historical Analyst Ratings1SXP Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15

Analyst Ratings Consensus

ChartMill Buy Consensus
76.84%
1SXP.DE was analyzed by 19 analysts. The buy percentage consensus is at 77. So analysts seem to be have mildly positive about 1SXP.DE.
In the previous month the buy percentage consensus was at a similar level.
1SXP.DE was analyzed by 19 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-01-26BerenbergMaintains Buy -> Buy
2025-12-12BerenbergUpgrade Hold -> Buy
2025-12-11STIFEL EUROPEMaintains Buy -> Buy
2025-12-11JefferiesMaintains Hold -> Hold

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 13, 2026
Period
Q2 / 2026
EPS Estimate
€0.22
Revenue Estimate
250.64M
Revenue Q2Q
-0.67%
EPS Q2Q
-15.03%
Number of Analysts
7

Next Earnings Revisions

Revenue (1 Month)
-1.74%
Revenue (3 Months)
-1.27%
EPS (1 Month)
-6.37%
EPS (3 Months)
-3.95%

Next Earnings Summary

1SXP.DE is expected to report earnings on 5/13/2026. The consensus EPS estimate for the next earnings is 0.22 EUR and the consensus revenue estimate is 250.64M EUR.
The next earnings revenue estimate has been revised downward by 1.27% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2032

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Revenue
YoY % growth
1SXP.DE revenue by date.1SXP.DE revenue by date.
898.602M
9.44%		957.091M
6.51%		986.21M
3.04%		1.029B
4.34%		1.101B
7.00%		1.175B
6.72%		1.253B
6.64%		1.333B
6.38%		1.567B
17.55%		1.663B
6.13%
EBITDA
YoY % growth
1SXP.DE ebitda by date.1SXP.DE ebitda by date.
217.822M
-2.54%		255.565M
17.33%		266.334M
4.21%		278.9M
4.72%		307.6M
10.29%		337.02M
9.56%		361.04M
7.13%		387.03M
7.20%		604.82M
56.27%		N/A
EBIT
YoY % growth
1SXP.DE ebit by date.1SXP.DE ebit by date.
171.174M
1.83%		190.587M
11.34%		186.894M
-1.94%		192.52M
3.01%		216.94M
12.68%		240.49M
10.86%		251.15M
4.43%		271.46M
8.09%		357.94M
31.86%		379.8M
6.11%
Operating Margin
1SXP.DE operating margin by date.1SXP.DE operating margin by date.
19.05%19.91%18.95%18.71%19.70%20.47%20.04%20.36%22.84%22.84%
EPS
YoY % growth
1SXP.DE eps by date.1SXP.DE eps by date.
N/A0.99
4.50%		0.97
-2.02%		0.95
-1.71%		1.09
14.40%		1.22
12.24%		1.31
7.20%		1.43
9.01%		N/AN/A

All data in EUR

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		0.22
-15.03%		0.26
-12.03%		0.26
20.08%
Revenue
Q2Q % growth		250.64M
-0.67%		268.32M
4.62%		266.07M
7.47%
EBITDA
Q2Q % growth		65.791M
-24.64%		73.665M
-37.29%		73.577M
-39.08%
EBIT
Q2Q % growth		44.249M
-10.94%		51.985M
-13.53%		51.735M
25.17%

All data in EUR

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

1SXP.DE Yearly Revenue VS Estimates1SXP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
1SXP.DE Yearly EPS VS Estimates1SXP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
8.07%
EPS Next 5 Year
8.08%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
5.35%
Revenue Next 5 Year
5.81%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
18.01%
EBIT Next 5 Year
13.55%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

SCHOTT PHARMA AG& CO KGAA / 1SXP.DE Forecast FAQ

What do analysts expect the price target to be for SCHOTT PHARMA AG& CO KGAA (1SXP.DE)?

19 analysts have analysed 1SXP.DE and the average price target is 19.93 EUR. This implies a price increase of 33.4% is expected in the next year compared to the current price of 14.94.

What is the next earnings date for 1SXP stock?

SCHOTT PHARMA AG& CO KGAA (1SXP.DE) will report earnings on 2026-05-13.

Can you provide the consensus estimates for SCHOTT PHARMA AG& CO KGAA next earnings?

The consensus EPS estimate for the next earnings of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 0.22 EUR and the consensus revenue estimate is 250.64M EUR.

What is the consensus rating for 1SXP stock?

The consensus rating for SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 76.8421 / 100 . This indicates that analysts generally have a positive outlook on the stock.